The DrugAge database of aging-related drugs

1Population aging is a major medical, social and economic challenge worldwide. Not surprisingly, identifying drugs and compounds that delay aging is of widespread importance (Moskalev et al., 2016), in particular, given recent advances in our understanding of the genetics of aging in model organisms (de Magalhaes et al., 2012). Indeed, dozens of studies have been performed in recent years in model organisms to assay compounds for longevity effects. The growing amount of data being generated increases the complexity of its analysis and the difficulty of placing findings in the context of previous studies. To help researchers study and prioritize drugs and compounds of relevance to aging, we developed DrugAge, a database of drugs and compounds that modulate aging. We also present our initial analyses and functional enrichment of DrugAge gene targets.

2DrugAge aims to provide high‐quality summary data on lifespan‐extending drugs and compounds in model organisms. Data were primarily assembled using literature searches (see Experimental Procedures in the Supporting information). Additionally, we used other databases and submissions from the scientific community, resulting in 324 research articles. DrugAge data focus solely on assays performed in standard conditions (Experimental Procedures in Supporting information). Only compounds, drugs and substances extending lifespan in a statistically significant manner in at least one experiment were included, but conflicting and negative results were then also added to those entries to provide a balanced literature survey.

3DrugAge is searchable based on fields such as the compound name, species or lifespan effect. The current version (build 2) of the database comprises 1316 lifespan assays using 418 distinct compounds on 27 unique model organisms (including 70 individual strains), in particular worms (481 entries), flies (365 entries), yeast (55 entries) and mice (70 entries). The data are presented as tables and interactive charts (Fig. 1). DrugAge is freely available online (http://genomics.senescence.info/drugs/), and data are also available for download. As we will continue to update DrugAge, we encourage feedback and further data submissions from the research community.

4We developed a user‐friendly interface to search and retrieve information from DrugAge (Fig. 1). Key experimental parameters for each assay (average/median lifespan, maximum lifespan, strain, dosage and gender, if available), citations and a link to the original PubMed record are provided. The data browser also features drug and organism records, enabling detailed exploration of the aggregated results for a specific drug or species. Moreover, we found that 214 of the 418 compounds/substances have a known biological interaction in drug interactions databases (Experimental Procedures in Supporting information). As such, users can identify interacting genes and proteins in tabular form, and in network diagrams.

5We found that the magnitude of mean/median lifespan changes per assay is species‐dependent and effects are more modest in mice when compared to lower organisms (Fig. 2A). The extent of maximum lifespan changes is more modest and not as dissimilar across species (Fig. S1, Supporting information). We also noted a linear correlation (r 2 = 0.73) between average/median and maximum lifespan changes (Fig. S2, Supporting information). Lastly, we found a strong correlation between average/median (r 2 = 0.77) and maximum (r 2 = 0.81) lifespan changes in males and females, suggesting a modest sexual dimorphism (Fig. S3, Supporting information).

6To analyse enriched processes in the targets of compounds in DrugAge, we used DGIdb (Wagner et al., 2016) to obtain a list of human gene interacting partners for all drugs in DrugAge (Experimental Procedures in Supporting information). Of 418 DrugAge compounds/substances, 90 were found to have a DGIdb record, resulting in a total of 411 distinct genes. Statistically significant enriched terms amongst gene targets of compounds in DrugAge include various functional categories related to glutathione and antioxidant activity, calcium and ion transport and metabolic processes (Fig. 2B for top results and Table S1, Supporting information for full results).

7We explored the overlap between DrugAge interacting genes and genes previously associated with aging. This was carried out by obtaining the 1124 human orthologues of genes that extend lifespan in model organisms using the GenAge database (Tacutu et al., 2013). Of the 1124 genes, 287 (25.5%) were known to interact with drugs in DGIdb (Wagner et al., 2016). Of these, 65 (29.3%) overlap with DrugAge targets (Fig. S4, Supporting information), when 38 would be expected by chance. As such, we identified a modest but significant (P‐value < 0.01) degree of overlap between the genes arising from the two databases.

8DrugAge was designed to complement and expand existing databases in the context of aging. In particular, the Human Ageing Genomic Resources (HAGR), also developed by some of us, offers a collection of online databases for understanding aging in both humans and model organisms (Tacutu et al., 2013). HAGR focuses mostly on genes, and thus there is a need for a curated database of drugs and compounds that can extend lifespan in model organisms. Existing databases with lifespan‐extending drugs include AgeFactDB (http://agefactdb.jenage.de/) (Huhne et al., 2014), in turn based on data from HAGR and SAGEWEB (http://sageweb.org/), and Geroprotectors.org (http://geroprotectors.org/) (Moskalev et al., 2015). DrugAge incorporates data from all these resources and improves on them by providing a more extensive and systematic repertoire of lifespan‐extending drugs, compounds and substances. Indeed, we followed the high standards for manual curation, user‐friendly interface and performance of HAGR (Tacutu et al., 2013). Besides, DrugAge integrates drug–gene interactions and cross‐links to aging‐related genes, allowing a deeper examination of lifespan‐extending drugs. Interestingly, we have noted a sharp increase in the number of drug assays carried out yearly post‐2000 (Fig. S5, Supporting information), indicating the timeliness of DrugAge and of pharmacological interventions in aging.

9Our initial analysis of DrugAge reveals various trends and insights. We observed that lifespan‐extending effects are more modest in mice than in lower organisms, as would be expected. In addition, we observed a strong correlation between average/median and maximum lifespan changes, as well as between lifespan‐extending effects in males and females. The significant but modest overlap between targets of lifespan‐extending drugs and known aging‐related genes suggests that some but not most aging‐related pathways have been targeted pharmacologically in longevity studies. Lastly, we explored functions and pathways enriched in the targets of lifespan‐extending drugs. The most relevant categories are related to glutathione and antioxidant activity, although a caveat to this analysis is that it does not take into account researcher biases in historically studying particular pathways and proteins (and the drugs targeting them) more than others.

10In conclusion, we developed a new database of lifespan‐extending compounds and drugs in model organisms that reflect our current knowledge of pharmacological manipulations of aging. Given its scientific quality and rigour, DrugAge will be the benchmark in the field and will be of great value to researchers.

11This work was supported by a Wellcome Trust grant (104978/Z/14/Z) to J.P.M, and funding from the Israel Ministry of Science and Technology to A.B.

12None declared.

13JPM conceived and coordinated the project. DB, DT and JPM analysed the data. DB, DT, HT, MW, SS, SF, AA, MF, PM, TG, RC, EADS, AB, NA, JG, MP, VEF, AZ, AM and JPM contributed reagents/materials/analysis tools. DB, DT and JPM wrote the manuscript.